US Pharma Tariffs Could Boost Drug Costs by $51 Billion Annually, New Report Warns

A recent analysis commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) reveals that imposing a 25% tariff on pharmaceutical imports could increase U.S. drug costs by nearly $51 billion each year. Conducted by Ernst & Young and reviewed by Reuters, the report highlights significant economic and public health risks associated with such tariffs.

Key Findings

• Import Value and Sources: In 2023, the U.S. imported pharmaceutical products worth $203 billion, with 73% coming from Europe, particularly Ireland, Germany, and Switzerland.

• Domestic Sales: Total sales of finished pharmaceuticals in the U.S. reached $393 billion in 2023.

• Potential Price Impact: If tariffs are fully passed on to consumers, drug prices in the U.S. could rise by up to 12.9%.

• Production Costs: About 30% of pharmaceutical imports are raw ingredients used in domestic manufacturing. Tariffs on these inputs could increase production costs by 41%, potentially reducing the global competitiveness of U.S.-made drugs.

• Export Concerns: The U.S. exports around 25% of its pharmaceutical output, valued at $101 billion. Increased input costs could threaten approximately 490,000 jobs linked to pharmaceutical exports by reducing foreign demand.

• Retaliatory Risks: The report did not factor in possible retaliatory tariffs from other countries, which could exacerbate the economic impact on U.S. drug producers.

Context and Industry Response

Pharmaceuticals have traditionally been exempt from trade disputes due to the critical nature of the products. However, former President Donald Trump has repeatedly threatened to impose a 25% tariff on drug imports, citing national security concerns over dependence on foreign production. The Trump administration recently launched investigations into pharmaceutical imports as part of this strategy.

PhRMA, representing major companies like Amgen, Bristol Myers Squibb, Eli Lilly, and Pfizer, argues that tariffs would undermine efforts to boost domestic manufacturing. Industry leaders are urging a gradual implementation of any tariffs to mitigate financial shocks and are actively seeking exemptions, as exemplified by Swiss company Roche’s recent petition.

Trade experts note that tariffs on finished products could be passed on to consumers via distributors, while tariffs on raw materials would increase production costs. Companies are using the ongoing Commerce Department investigation to advocate for alternatives to tariffs that support domestic production without inflating drug prices.

Implications

The report underscores the delicate balance between protecting domestic pharmaceutical manufacturing and maintaining affordable drug prices for American consumers. Policymakers face a complex challenge in addressing national security concerns without triggering significant cost increases or job losses in the pharmaceutical sector.

Disclaimer

This article is based on a report commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA) and analyzed by Ernst & Young. The findings and projections reflect the data and assumptions available as of April 2025. The actual impact of tariffs on drug prices and the pharmaceutical industry may vary depending on policy decisions, market responses, and other economic factors.